---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-068798"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2023-12-07T23:59:59+00:00"
generated_at: "2026-06-07T16:10:09.951073+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Axsome hosts solriamfetol investor day with expert panel covering MDD, ADHD, BED, and sleep disorders

## Summary
- Virtual investor event held Dec 7, 2023, featuring five physician thought leaders discussing solriamfetol.
- Indications covered: MDD, ADHD, binge eating disorder, OSA/EDS (SHARP study), and shift work disorder.
- Axsome management provided overview of clinical development plans for solriamfetol.
- No specific clinical data, financial results, or pipeline milestones disclosed in the press release.

## SEC filing metadata
- accession: 0000950170-23-068798
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2023-12-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/0000950170-23-068798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017023068798/axsm-20231207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-068798
- JSON: https://secwatch.observer/filing/0000950170-23-068798.json
- Plain text: https://secwatch.observer/filing/0000950170-23-068798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.